EP3307714A1 - An improved method for the synthesis and purification of pirfenidone - Google Patents

An improved method for the synthesis and purification of pirfenidone

Info

Publication number
EP3307714A1
EP3307714A1 EP15712704.4A EP15712704A EP3307714A1 EP 3307714 A1 EP3307714 A1 EP 3307714A1 EP 15712704 A EP15712704 A EP 15712704A EP 3307714 A1 EP3307714 A1 EP 3307714A1
Authority
EP
European Patent Office
Prior art keywords
pirfenidone
process according
pyridone
methyl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15712704.4A
Other languages
German (de)
French (fr)
Inventor
Hasan KOYUNCU
Emre AKGOL
Omer Reis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ulkar Kimya Sanayii Ve Ticaret A S
Original Assignee
Ulkar Kimya Sanayii Ve Ticaret A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ulkar Kimya Sanayii Ve Ticaret A S filed Critical Ulkar Kimya Sanayii Ve Ticaret A S
Publication of EP3307714A1 publication Critical patent/EP3307714A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6

Definitions

  • This invention relates to an improved process for the preparation and purification of pirfenidone.
  • Pirfenidone (1) is a small molecule whose chemical name is 5-methyl-1-phenyl-2-(1 H)- pyridone. Its use for the manufacture of a medicament for the preparation and/or prevention of fibrotic lesions is first described in EP0383591.
  • Pirfenidone is typically synthesized by copper catalyzed N-arylation of 5-methyl-2-pyridone with bromobenzene or iodobenzene, generally at elevated temperatures. There are generally two approaches to the copper catalyzed synthesis of pirfenidone starting from 5-methyl-2- pyridone: i. The use of iodobenzene or bromobenzene as solvent.
  • EP2440543 explains the synthesis of pirfenidone (1) from 5-methyl-2-pyridone (2) and excess bromobenzene (1.8 mol eq) (4) with Cu 2 0 catalysis to obtain crude pirfenidone in 85% yield:
  • Pirfenidone is a small neutral molecule. The absence of acidic or basic sites prevents the isolation and purification of pirfenidone through the formation of salts. As mentioned above, means for isolation or purification of pirfenidone is limited to solvent precipitations/crystallizations. Thus it would be highly advantageous to have additional means of purification for pirfenidone free from reagents, colored impurities and residual solvents etc.
  • the present invention provides a process for the synthesis of pirferidone by reacting 5-methyl-2-pyridone with a low quantity of bromobenzene in a low quantity of polar aprotic solvent in the presence of a copper catalyst and a base.
  • the present invention also provides a method for purification of pirfenidone by initially synthesizing an acid adduct of pirfenidone from crude pirfenidone and then recovering pirfenidone with increased purity.
  • the present invention is a process for the synthesis of pirfenidone (1)
  • said process comprising the steps of; reacting 5-methyl-2-pyridone (2),
  • 5-methyl-2-pyridone (2) is reacted with preferably 1 ,2 - 1 ,4 mole equivalent of bromobenzene.
  • the polar aprotic solvent can be selected from dimethylsulfoxide (DMSO), hexamethylphosphoramide (HMPA) and their mixtures thereof.
  • DMSO dimethylsulfoxide
  • HMPA hexamethylphosphoramide
  • the reaction is carried out in DMSO wherein DMSO is used as 0, 1-1 volume equivalent with respect to weight of 5-methyl-2-pyridone (2).
  • the reaction is carried out in 0,5 volume equivalent DMSO with respect to weight of 5-methyl- 2-pyridone (2).
  • the reaction is carried out in the presence of Cu(l) or Cu(ll) salts, such as CuCI, CuBr, Cul, Cu 2 0, Cu(OAc), Cu(OAc) 2 .
  • the reaction is carried out in the presence of Cu 2 0 or CuBr, wherein the appropriate Cu salt is used in catalytical amount which means that less than stoichiometric amount.
  • the reaction can be carried out in the presence of a base selected from K 2 C0 3 Na 2 C0 3 , Na 3 P0 4 , K 3 P0 4 .
  • the reaction is carried out in the presence 2 C0 3 .
  • reaction is optionally carried out in the presence of an additional base wherein the additional base is 0,05-0,30 mole equivalent of sodium acetate (NaOAc), preferably 0,2 mole equivalent of NaOAc with respect to 5-methyi-2-pyridone (2).
  • additional base is 0,05-0,30 mole equivalent of sodium acetate (NaOAc), preferably 0,2 mole equivalent of NaOAc with respect to 5-methyi-2-pyridone (2).
  • the reaction is carried out at temperatures sufficient to form pirfenidone, preferably >100°C, more preferably >120°C or most preferably at 135-140°C.
  • pirfenidone can be isolated from the reaction mixture by traditional methods.
  • pirfenidone Being a neutral molecule, pirfenidone can only form adducts with strong acids. Acids with pKa>0 was unable to induce adduct formation. Acids with pKa ⁇ 0 are useful acids for adduct formation and isolation. For example, pirfenidone cannot form adducts with acetic acid and phosphoric acid.
  • suitable acids that may form stable adducts with pirfenidone (1) in step a are acids with pKa ⁇ 0.
  • suitable acids used in adduct formation are selected from the group of sulfuric acid (H 2 S0 4 ), hydrochloric acid (HCI), hydrobromic acid (HBr), hydroiodic acid (HI), and methanesulfonic acid (MsOH).
  • strong acid that may form stable adducts with pirfenidone (1) in step a is preferably H 2 S0 4 .
  • the acid adduct formation reaction in step a can be carried out in a solvent selected from acetone, tetrahydrofuran (THF), acetic acid, ethyl acetate, dichloromethane and their mixtures or their mixtures with nonpolar solvents, such as toluene.
  • a solvent selected from acetone, tetrahydrofuran (THF), acetic acid, ethyl acetate, dichloromethane and their mixtures or their mixtures with nonpolar solvents, such as toluene.
  • THF tetrahydrofuran
  • acetic acid acetic acid
  • ethyl acetate dichloromethane
  • dichloromethane dichloromethane
  • nonpolar solvents such as toluene
  • recovery of pirfenidone (1) from pirfenidone adduct (5) in step b can be carried out in a solvent in the presence of a base which is basic enough to neutralize the adduct of formula (5).
  • the base is NaOH.
  • the solvent of step b can be water in which pirfenidone will precipitate after neutralization of the acid adduct form with a suitable base.
  • the solvent can also be an organic solvent such as methanol in which pirfenidone acid adduct can be neutralized.
  • the present invention provides a process for the synthesis and purification of pirfenidone free of major drawbacks of the processes presented in the prior art: a.
  • the use low quantity of bromobenzene (4) is more cost effective and environmentally friendly.
  • the lower quantities of residual bromobenzene (4) in the crude pirfenidone (1) product simplify the isolation and purification process and affect the yields in a positive manner.
  • Pirfenidone acid adduct compounds are highly soluble in water and soluble in alcohols. Thus, pirfenidone can be recovered easily by dissolving it in a proper media, final filtration followed by neutralization with a base. This process also serves as a final purification of pirfenidone to get the product in a pharmaceutically acceptable purity and form.
  • the following examples will illustrate the synthesis, isolation, formation of acid adducts of pirfenidone and recovery of pure pirfenidone from the adduct. These examples should not, however, be construed as limiting the invention:
  • 5-methyl-2-pyridone (2) (20 g, 0,18 mol), K 2 C0 3 (30,4 g, 0,22 mol), NaOAc (3 g, 0,036 mol, 0,2 mol eq), CuBr (2,62 g, 0,018 mol, 0.1 mol eq) [or Cu 2 0 (1 ,29 g, 0,05 mol eq)], Bromobenzene (4) (40,28 g, 0,26 mol, 1 ,4 mol eq) and DMSO (10 mL, 0,5 V eq) was placed in a round bottom flask under a nitrogen atmosphere. Flask was heated to 135-140°C and stirred at this temperature for 6-8 h.
  • reaction medium was cooled down to about 60 °C. Then, 100 mL water was added to the reaction mixture followed by 4 mL NH 4 OH and 100 mL toluene. The resulting mixture was stirred for 15 min and the phases were separated. Aqueous phase was extracted with 2x50 mL toluene then organic phases were combined (all extractions were carried out at about 60°C). Combined organic phases were filtered over a bed of celite after treatment with charcoal. After evaporation of toluene to the dryness, 36,3 g crude pirfenidone was obtained. Crude pirfenidone purity is >99,5% (HPLC analysis, UV detector 310 nm).
  • Precipitated product was filtered, washed with 1 volume equivalent cold acetone and dried in an oven at 50-60°C to furnish pirfenidone adduct in 97-99% yield based on a 1 :1 Pirfenidone:H 2 S0 4 .
  • Precipitated product was filtered, washed with 1 volume equivalent cold acetone and dried in an oven at 50-60°C to furnish 48 g pirfenidone adduct in 94% overall yield and 99.8% purity starting from 5-methyl-2-pyridone.
  • the obtained product is a white solid completely free from Bromobenzene.
  • Pirfenidone H 2 S0 4 adduct obtained in example D was treated as described in example C to obtain 29,3 g pure Pirfenidone in 86% overall yield starting from 5-methyl-2-pyridone and >99,9% purity.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present invention provides a process for the synthesis of pirferidone by reacting 5-methyl-2-pyridone with a low quantity of bromobenzene in a low quantity of polar aprotic solvent in the presence of a copper catalyst and a base. The present invention also provides a method for purification of pirfenidone by initially synthesizing an acid adduct of pirfenidone from crude pirfenidone and then recovering pirfenidone with increased purity.

Description

AN IMPROVED METHOD FOR THE SYNTHESIS AND PURIFICATION OF PIRFENIDONE
This invention relates to an improved process for the preparation and purification of pirfenidone.
Pirfenidone (1) is a small molecule whose chemical name is 5-methyl-1-phenyl-2-(1 H)- pyridone. Its use for the manufacture of a medicament for the preparation and/or prevention of fibrotic lesions is first described in EP0383591.
BRIEF DESCRIPTION OF THE PRIOR ART
Pirfenidone is typically synthesized by copper catalyzed N-arylation of 5-methyl-2-pyridone with bromobenzene or iodobenzene, generally at elevated temperatures. There are generally two approaches to the copper catalyzed synthesis of pirfenidone starting from 5-methyl-2- pyridone: i. The use of iodobenzene or bromobenzene as solvent.
ii. The use of polar aprotic solvent, such as DMF, in the presence of excess bromobenzene. In this approach, solvent DMF presumably also acts as a supporting ligand for copper catalyst.
US3974281 and US3839346 describe the preparation of pirfenidone (1) starting from 5- methyl-2-pyridone (2) in the presence of anhydrous sodium carbonate, copper powder, iodobenzene (3), under reflux for 18 hours, furnishing crude pirfenidone (1), which after then crystallized in benzene and petroleum ether and obtained in a yield of 85%.
EP2440543 explains the synthesis of pirfenidone (1) from 5-methyl-2-pyridone (2) and excess bromobenzene (1.8 mol eq) (4) with Cu20 catalysis to obtain crude pirfenidone in 85% yield:
Those above mentioned methods have some major drawbacks: i. When the iodobenzene or bromobenzene reagent is used as solvent or in excess quantities, their removal from the initially obtained crude product requires the use of large amounts nonpolar solvents; like heptane, hexane, pentane or petroleum ether. These solvents have the proper solubilizing power for iodo- or bromobenzene residues whereas they only poorly dissolve the product pirfenidone. Besides, the use of excess reagents and large amounts of solvents leads to higher manufacturing costs and environmental problems. Thus it would be highly advantageous minimizing the quantities of these reagents and solvents both from economic and environmental point of view. ii. When the reaction is run in the presence of polar aprottc solvents like DMF like in EP2440543, the product isolation gets complicated, directly affecting the product yields.
In order to prevent the product loss due to the presence of DMF, it must be removed by aqueous washes prior to crude product isolation. Since pirfenidone presents remarkable aqueous solubility, product loss during extractions to the aqueous phases is inevitable unless the aqueous phases are saturated with salts. However, using saturated salt solutions for aqueous extractions would prevent the effective removal of DMF from the organic phase that in turn affects the product isolation yield. In fact, EP244053 teaches that an optimal sodium chloride solution is high enough to minimize the loss of pirfenidone in the aqueous layer, but low enough to allow maximum amount of DMF in the aqueous layer. Thus it would be highly advantageous to have a method that utilizes minimum amount of polar organic solvents like DMF to increase the yields and simplify the manufacturing process.
iii. Pirfenidone is a small neutral molecule. The absence of acidic or basic sites prevents the isolation and purification of pirfenidone through the formation of salts. As mentioned above, means for isolation or purification of pirfenidone is limited to solvent precipitations/crystallizations. Thus it would be highly advantageous to have additional means of purification for pirfenidone free from reagents, colored impurities and residual solvents etc.
To overcome the disadvantages of the state of art, the present invention provides a process for the synthesis of pirferidone by reacting 5-methyl-2-pyridone with a low quantity of bromobenzene in a low quantity of polar aprotic solvent in the presence of a copper catalyst and a base. The present invention also provides a method for purification of pirfenidone by initially synthesizing an acid adduct of pirfenidone from crude pirfenidone and then recovering pirfenidone with increased purity. DETAILED DESCRIPTION OF THE INVENTION
The present invention is a process for the synthesis of pirfenidone (1),
said process comprising the steps of; reacting 5-methyl-2-pyridone (2),
with bromobenzene (4),
in a polar aprotic solvent, in the presence of Cu(l) or Cu(ll) salts and a base, wherein bromobenzene (3) is used as 1 to 1 ,5 mole equivalent of 5-methyl-2-pyridone (2) and the polar protic solvent is used as 0,1-1 volume equivalent with respect to weight of 5-methyl-2- pyridone (2).
According to the invention, 5-methyl-2-pyridone (2) is reacted with preferably 1 ,2 - 1 ,4 mole equivalent of bromobenzene. According to the invention the polar aprotic solvent can be selected from dimethylsulfoxide (DMSO), hexamethylphosphoramide (HMPA) and their mixtures thereof. In a preferred embodiment the reaction is carried out in DMSO wherein DMSO is used as 0, 1-1 volume equivalent with respect to weight of 5-methyl-2-pyridone (2). In a more preferred embodiment the reaction is carried out in 0,5 volume equivalent DMSO with respect to weight of 5-methyl- 2-pyridone (2).
According to the invention the reaction is carried out in the presence of Cu(l) or Cu(ll) salts, such as CuCI, CuBr, Cul, Cu20, Cu(OAc), Cu(OAc)2. In a preferred embodiment the reaction is carried out in the presence of Cu20 or CuBr, wherein the appropriate Cu salt is used in catalytical amount which means that less than stoichiometric amount. According to the present invention, the reaction can be carried out in the presence of a base selected from K2C03 Na2C03, Na3P04, K3P04. In a preferred embodiment the reaction is carried out in the presence 2C03. !n a more preferred embodiment the reaction is optionally carried out in the presence of an additional base wherein the additional base is 0,05-0,30 mole equivalent of sodium acetate (NaOAc), preferably 0,2 mole equivalent of NaOAc with respect to 5-methyi-2-pyridone (2).
According to the invention the reaction is carried out at temperatures sufficient to form pirfenidone, preferably >100°C, more preferably >120°C or most preferably at 135-140°C.
According to the invention pirfenidone can be isolated from the reaction mixture by traditional methods.
Another embodiment of the present invention is a process for the purification of pirfenidone
(1).
1 wherein said process comprising the steps of; a) formation of an acid adduct compound (5)
by reacting pirfenidone or crude pirfenidone with HX, wherein HX is a strong acid with pKa<0 and, b) recovering the pirfenidone (1) from acid adduct compound (5).
Crude pirfenidone is unpurified isolated reaction product with any level of purity.
Being a neutral molecule, pirfenidone can only form adducts with strong acids. Acids with pKa>0 was unable to induce adduct formation. Acids with pKa<0 are useful acids for adduct formation and isolation. For example, pirfenidone cannot form adducts with acetic acid and phosphoric acid.
According to the invention, suitable acids that may form stable adducts with pirfenidone (1) in step a are acids with pKa<0. Preferably suitable acids used in adduct formation are selected from the group of sulfuric acid (H2S04), hydrochloric acid (HCI), hydrobromic acid (HBr), hydroiodic acid (HI), and methanesulfonic acid (MsOH).
According to the invention, strong acid that may form stable adducts with pirfenidone (1) in step a is preferably H2S04.
According to the invention, the acid adduct formation reaction in step a can be carried out in a solvent selected from acetone, tetrahydrofuran (THF), acetic acid, ethyl acetate, dichloromethane and their mixtures or their mixtures with nonpolar solvents, such as toluene. In a preferred embodiment the reaction is carried out in acetone.
According to the invention, recovery of pirfenidone (1) from pirfenidone adduct (5) in step b can be carried out in a solvent in the presence of a base which is basic enough to neutralize the adduct of formula (5). In a preferred embodiment the base is NaOH. According to the invention, the solvent of step b can be water in which pirfenidone will precipitate after neutralization of the acid adduct form with a suitable base. The solvent can also be an organic solvent such as methanol in which pirfenidone acid adduct can be neutralized.
The present invention provides a process for the synthesis and purification of pirfenidone free of major drawbacks of the processes presented in the prior art: a. The use low quantity of bromobenzene (4) is more cost effective and environmentally friendly. The lower quantities of residual bromobenzene (4) in the crude pirfenidone (1) product simplify the isolation and purification process and affect the yields in a positive manner.
b. Easy removal of low quantities of DMSO with aqueous washes simplifies the process.
The lack of considerable quantities of residual DMSO after aqueous washes also simplifies the crude product isolation and has a positive impact on the yields.
c. Formation of stable adducts with strong acids provided a strong leverage for the quick and quantitative formation of pirfenidone adduct through which non-polar impurities and residual bromobenzene was removed completely together with colored impurities. Pirfenidone acid adduct compounds are highly soluble in water and soluble in alcohols. Thus, pirfenidone can be recovered easily by dissolving it in a proper media, final filtration followed by neutralization with a base. This process also serves as a final purification of pirfenidone to get the product in a pharmaceutically acceptable purity and form. The following examples will illustrate the synthesis, isolation, formation of acid adducts of pirfenidone and recovery of pure pirfenidone from the adduct. These examples should not, however, be construed as limiting the invention:
Examples:
A) Synthesis of Crude Pirfenidone:
5-methyl-2-pyridone (2) (20 g, 0,18 mol), K2C03 (30,4 g, 0,22 mol), NaOAc (3 g, 0,036 mol, 0,2 mol eq), CuBr (2,62 g, 0,018 mol, 0.1 mol eq) [or Cu20 (1 ,29 g, 0,05 mol eq)], Bromobenzene (4) (40,28 g, 0,26 mol, 1 ,4 mol eq) and DMSO (10 mL, 0,5 V eq) was placed in a round bottom flask under a nitrogen atmosphere. Flask was heated to 135-140°C and stirred at this temperature for 6-8 h. After the completion of the reaction according to HPLC analysis, reaction medium was cooled down to about 60 °C. Then, 100 mL water was added to the reaction mixture followed by 4 mL NH4OH and 100 mL toluene. The resulting mixture was stirred for 15 min and the phases were separated. Aqueous phase was extracted with 2x50 mL toluene then organic phases were combined (all extractions were carried out at about 60°C). Combined organic phases were filtered over a bed of celite after treatment with charcoal. After evaporation of toluene to the dryness, 36,3 g crude pirfenidone was obtained. Crude pirfenidone purity is >99,5% (HPLC analysis, UV detector 310 nm).
B) Formation of Pirfenidone: H2S04 adduct:
85 g pirfenidone (1) was placed in round bottom flask followed by 3 volume equivalent of acetone and heated to 40-45°C. After complete dissolution of, 1.0-1.1 mol equivalent of H2S04 was added slowly through a dropping funnel so as to keep the reaction temperature below 50°C. After completion of the addition, an extra 1 volume equivalent of acetone was added to the reaction mixture through the addition funnel. Reaction mixture was stirred for 3- 4 hr at room temperature, then cooled to ~-5°C and further stirred for 3-4 hours. Precipitated product was filtered, washed with 1 volume equivalent cold acetone and dried in an oven at 50-60°C to furnish pirfenidone adduct in 97-99% yield based on a 1 :1 Pirfenidone:H2S04.
C) Recovery of Pirfenidone from pirfenidone: H2S04 adduct: 24 g pirfenidone adduct (5) was placed in a round bottom flask together with 2 volume equivalent of MeOH. Mixture was heated to 40-45°C and the starting material was dissolved completely. A separately prepared solution of 2.0-2.2 mol equivalent NaOH dissolved in 4 volume equivalent of MeOH was slowly added during which formation and precipitation of insoluble inorganic salts was observed. After completion of addition, mixture was further stirred for 15-20 min and filtered to obtain a clear solution of pirfenidone. This resulting clear solution can be evaporated and used for further purification if necessary or can be evaporated to dryness to get a solid product. For example, in our case, to the residue was added 2 volume equivalent water (based on the expected product) and heated to ~80°C to obtain a two phase system or a clear solution based on the amount of residual eOH in the original residue. Afterwards, solution was cooled to ambient temperature, then to ~-5°C for 4- 5h. Then product was filtered, washed with cold water and dried in an oven ~50°C to obtain 14.4-14.7 g white product (90-92% based on the pirfenidone: H2S04 1 :1 adduct). D) Formation of Pirfenidone: H2S04 adduct from crude Pirfenidone:
36,3 g crude pirfenidone (from example A) was placed in round bottom flask followed by 3 volume equivalent of acetone and heated to 40-45°C. After complete dissolution, 1.0-1.1 mol equivalent of H2S04 was slowly added through a dropping funnel so as to keep the reaction temperature below 50°C. After the completion of the addition, an extra 1 volume equivalent of acetone was added to the reaction mixture through the addition funnel. Reaction mixture was allowed to cool to room temperature and stirred for 1 hr, then cooled to ~-5°C and further stirred for 4-5 hr at this temperature. Precipitated product was filtered, washed with 1 volume equivalent cold acetone and dried in an oven at 50-60°C to furnish 48 g pirfenidone adduct in 94% overall yield and 99.8% purity starting from 5-methyl-2-pyridone. The obtained product is a white solid completely free from Bromobenzene.
E) Formation of pure Pirfenidone:
Pirfenidone: H2S04 adduct obtained in example D was treated as described in example C to obtain 29,3 g pure Pirfenidone in 86% overall yield starting from 5-methyl-2-pyridone and >99,9% purity.

Claims

1. A process for the synthesis of pirfenidone 1 ),
said process comprising the steps of; reacting 5-methyl-2-pyridone (2),
with bromobenzene (4),
in a polar aprotic solvent, in the presence of Cu(l) or Cu(ll) salts and a base, wherein bromobenzene (3) is used as 1 to 1 ,5 mole equivalent of 5-methyl-2-pyridone (2) and the polar protic solvent is used as 0,1-1 volume equivalent with respect to weight of 5- methyl-2-pyridone (2).
2. A process according to claim 1 , wherein 5-methyl-2~pyridone (2) is reacted with preferably 1 ,2 - 1,4 mole equivalent of bromobenzene.
3. A process according to claims 1 , wherein the polar aprotic solvent is selected from DMSO, HMPA and mixtures thereof.
4. A process according to claim 3, wherein the polar aprotic solvent is DMSO.
5. A process according to claim 1 , wherein DMSO is used as 0,5 volume equivalent with respect to weight of 5-methyl-2-pyridone (2).
6. A process according to claim 1 , wherein the Cu(l) or Cu(ll) salt is selected from CuCI, CuBr, Cul, Cu20, Cu(OAc), Cu(OAc)2, preferably Cu20 or CuBr.
7. A process according to claim 1 , wherein the base is selected from K2C03 Na2C03, Na3P04l K3PO4, preferably is K2C03.
8. A process according to claim 7, wherein the reaction is optionally carried out in the presence of an additional base wherein the additional base is 0,05-0,30 mole equivalent of NaOAc, preferably 0,2 mole equivalent with respect to 5-methyl-2-pyridone (2).
9. A process according to claim 1 , wherein the reaction is carried out at temperatures sufficient to form pirfenidone, preferably >100°C, more preferably >120°C or at 135- 140°C.
10. A process for the purification of pirfenidone 1 ),
wherein the said process comprising the steps of;
a) formation of an acid adduct com ound (5)
by reacting crude pirfenidone with a strong acid HX, wherein HX is a strong acid with pKa<0 and, b) recovering the pirfenidone (1) from acid adduct compound (5).
11. A process according to claim 10, wherein the strong acid is selected from the group of H2S04, HCI, HBr, HI, and MsOH.
12. A process according to claim 1 , wherein the strong acid HX is H2S04.
13. A process according to claim 10-12, wherein step a is carried out in an organic solvent.
14. A process according to claim 13, wherein the solvent is selected from acetone, THF, acetic acid, ethyl acetate, dichloromethane and their mixtures or their mixtures with nonpolar solvents.
15. A process according to claim 10, wherein step b is carried out in the presence of a base.
16. A process according to claim 15, wherein the base is NaOH.
17. An acid adduct form of pirfenidone of formula (5), wherein HX is a strong acid with pKa<0.
5
18. The use of acid adduct form of pirfenidone of formula (5) for the preparation of pirfenidone.
EP15712704.4A 2015-01-26 2015-01-26 An improved method for the synthesis and purification of pirfenidone Withdrawn EP3307714A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2015/000030 WO2016122420A1 (en) 2015-01-26 2015-01-26 An improved method for the synthesis and purification of pirfenidone

Publications (1)

Publication Number Publication Date
EP3307714A1 true EP3307714A1 (en) 2018-04-18

Family

ID=52745934

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15712704.4A Withdrawn EP3307714A1 (en) 2015-01-26 2015-01-26 An improved method for the synthesis and purification of pirfenidone

Country Status (2)

Country Link
EP (1) EP3307714A1 (en)
WO (1) WO2016122420A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11066368B2 (en) 2016-01-14 2021-07-20 Laurus Labs Limited Process for the preparation and particle size reduction of pirfenidone
IT201600108927A1 (en) * 2016-10-27 2018-04-27 Dipharma Francis Srl METHOD FOR SYNTHESIZING AN ANTI-BIBROCT MEDICINE
US20180009753A1 (en) 2016-07-08 2018-01-11 Dipharma Francis S.R.L. Method for preparing an antifibrotic agent
WO2018083709A1 (en) * 2016-11-07 2018-05-11 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of pure 5-methyl-1-phenyl-2-1 (h)-pyridone
WO2018178996A1 (en) * 2017-03-28 2018-10-04 Natco Pharma Limited Improved process for the preparation of pirfenidone

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1049411A (en) 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US3839346A (en) 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
US4755742A (en) 1986-04-30 1988-07-05 Tektronix, Inc. Dual channel time domain reflectometer
JPH02215719A (en) 1989-02-15 1990-08-28 Yamauchi Akitomo Agent for repairing fibrosing lesion tissue and preventing fibrosing lesion
KR100898888B1 (en) * 2001-08-06 2009-05-21 시오노기세이야쿠가부시키가이샤 Process for preparation of 5-methyl-1-phenyl-21h-pyridinone
TWI434833B (en) 2009-06-03 2014-04-21 Intermune Inc Improved method for synthesizing pirfenidone

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2016122420A1 *

Also Published As

Publication number Publication date
WO2016122420A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
WO2016122420A1 (en) An improved method for the synthesis and purification of pirfenidone
JP5214615B2 (en) Process for preparing halogenated N-alkylnaltrexone
TWI453202B (en) Process and intermediates for preparing lapatinib
CA2988594C (en) Methods of making protein deacetylase inhibitors
KR101420892B1 (en) Process for the preparation of Imatinib and intermediates thereof
EP3490973B1 (en) Polymorphic forms of belinostat and processes for preparation thereof
CN118344381A (en) Process for preparing 1, 3-benzodioxole heterocyclic compounds
JP2009503034A (en) Process for producing 7H-pyrrolo [2,3-d] pyrimidine derivative
JP7144873B2 (en) Method for producing sugammadex sodium salt
US9834561B2 (en) Process for preparing ibrutinib and its intermediates
KR20120107461A (en) Process for preparing a phenylalanine derivative
JP2013216655A (en) Improved preparation method of blonanserin
JP2004520446A (en) Crystallization method of losartan potassium
CN105622380B (en) Preparation method of apremilast and intermediate thereof
US20060142595A1 (en) Process for preparing 5,6-dihydro-4-(S)-(ethylamino)-6-(S) methyl-4H-thieno[2,3b]thiopyran-2-sulphonamide-7,7-dioxide HCI
CN113956204A (en) Synthesis method of anserine
JP4319292B2 (en) Method for producing tert-butoxycarbonyl chloride
TWI364282B (en) Cefcapene pivoxil methanesulfonic acid salt
EP1849777B1 (en) Process for obtaining a valsartan salt useful for obtaining valsartan
CN104592222A (en) Preparation method for antiplatelet medicine AZD6482
JP4519564B2 (en) Method for purifying and producing 1-aminocyclopropanecarboxylic acid
US11286254B2 (en) Process for the synthesis of 2-benzhydryl-3 quinuclidinone
KR100963520B1 (en) An improved process for the preparation of irbesartan
CN107056801B (en) A kind of synthetic method of 4,5,6,7- thiophane simultaneously [3,2-c] pyridine hydrochloride
JPH01197478A (en) Production of n-(2-chlorobenzyl)-2-(2-thienyl) ethylamine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20171222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20190812

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200103